306293-36-7

Basic information

• Product Name: 4-[1-(2,4-Dimethyl-3-pyridinylcarbonyl)-4-methyl-4-piperidinyl}-2(S)-methyl-1-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]piperazine
• Synonyms: AD-101; SCH-350581
• CAS NO: 306293-36-7
• Molecular Formula: C₂₈H₃₇F₃N₄O
• Molecular Weight: 502.62849
• Mol File: 306293-36-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-[1-(2,4-Dimethyl-3-pyridinylcarbonyl)-4-methyl-4-piperidinyl}-2(S)-methyl-1-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[1-(2,4-Dimethyl-3-pyridinylcarbonyl)-4-methyl-4-piperidinyl}-2(S)-methyl-1-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]piperazine(306293-36-7)
• EPA Substance Registry System: 4-[1-(2,4-Dimethyl-3-pyridinylcarbonyl)-4-methyl-4-piperidinyl}-2(S)-methyl-1-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]piperazine(306293-36-7)

Safety Data

• Hazardous Substances Data: 306293-36-7(Hazardous Substances Data)

Upstream product

• 55314-30-2 2,4-dimethylnicotinic acid 
• 544704-12-3 2-methyl-4-(4-methylpiperidin-4-yl)-1-[1-(4-trifluoromethylphenyl)ethyl]piperazine 
• 709-63-7 1-(4-trifluoromethylphenyl)ethanone 
• 74879-18-8 (S)-2-methylpiperazine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1737-26-4 (R)-1-[4-(trifluoromethyl)phenyl]ethan-1-ol 
• 147081-29-6 (S)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 306296-86-6 [(1R)-1-[4-(trifluoromethyl)phenyl]ethyl] methanesulfonate 
• 306296-89-9 (S)-2-Methyl-1-[(S)-1-(4-trifluoromethyl-phenyl)-ethyl]-piperazine 
• 306296-87-7 1-[4(trifluoromethyl)-α(S)-methylbenzyl]-2(S)-methyl-4-(tert-butoxycarbonyl)piperazine 
• 306297-00-7 tert-butyl 4-methyl-4-((S)-3-methyl-4-((S)-1-(4-(trifluoromethyl)phenyl)ethyl)piperazin-1-yl)piperidine-1-carboxylate 
• 306296-99-1 4-Cyano-4-{(S)-3-methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS

The use is described of CCR5 antagonists of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R 1 is hydrogen or alkyl; R 2 is substituted phenyl, substituted heteroary

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4methyl-4-[3(S)-methyl-4-[1(S)-[4- (trifluoromethyl) phenyl]ethyl]-1-piperazinyl]piperidine N1-oxide (Sch-350634), an orally bioavailable, poten

Truncation of the original piperidino-2(S)-methyl piperazine lead structure 2, from a family of muscarinic antagonists, gave compound 8 which has improved selectivity for the HIV-1 co-receptor CCR5 over muscarinic receptors. Further optimization for pharm